Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex class II, DR beta chain (commonly referred to as the HLA-DRB chain) is an integral membrane protein forming the beta subunit of the HLA-DR antigen-presenting heterodimer. Together with the DR alpha chain, it constitutes the binding groove for peptide antigens derived from extracellular proteins. This complex is a cornerstone of the adaptive immune response, as it presents processed antigens to CD4+ helper T cells, orchestrating immunity and tolerance[1][2][3]. The gene encoding this chain is highly polymorphic, with multiple alleles conferring susceptibility to autoimmune disease, resistance to infections, and influencing transplant compatibility. While "DR beta 9" is not recognized as a canonical, functional human DR beta locus, the general biological role of the DR beta chain is critical in immune system regulation and disease pathogenesis. *If more precise information about “DR beta 9” is required (e.g., its sequence, expression, or disease linkage), authoritative immunogenetic resources should be consulted as this designation appears non-standard or improperly referenced.*
Blockade of antigen presentation; Inhibition of T cell activation; Reduction of immune response or autoimmunity; Modulation of MHC class II expression at the transcriptional level
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex class II, DR beta 9 chain (HLA-DRB9).